Objectives: Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers are synthetic sequence-selective interstrand DNA minor-groove cross-linking agents developed from anthramycins. We investigated the antibacterial activity of three dimers, SJG-136, DRG-16 and ELB-21, which differ in the structure of the PBD monomeric unit and the length of the linker region between the two identical PBD monomers.
Introduction
Over the last two decades, drug-resistant Gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA), multiresistant coagulase-negative staphylococci, penicillinresistant Streptococcus pneumoniae and vancomycin-resistant enterococci (VRE), have emerged worldwide. Although panresistant Gram-positive isolates have yet to appear, MRSA and VRE infections in particular are becoming more difficult to treat. 1 The recent introduction of novel antibacterial agents such as quinupristin/dalfopristin (type B/type A streptogramins) and linezolid (an oxazolidinone) has provided efficacious and safe treatment options for MRSA and VRE infections, but there remains an urgent need for new therapies, particularly as some VRE strains are already showing decreased susceptibility to these agents. 2, 3 As therapeutic options decrease, there has been recent interest in the development of agents that exert their antibacterial effects by binding selectively to specific sequences of duplex DNA. For example, small molecules derived from polyheterocyclic antibiotics based on distamycin have emerged recently as candidates for clinical development. 4, 5 These molecules are active against Gram-positive isolates such as streptococci, staphylococci and enterococci and exert their bactericidal effects by binding within the minor groove of DNA at A:T-rich sites commonly found in bacterial promoters and origins of replication. Their in vitro potencies are comparable to vancomycin and linezolid, they show efficacy against MRSA in murine models of acute infection and they display no genotoxicity. 5 The pyrrolo [2,1-c] [1, 4] benzodiazepines (PBDs) are a family of DNA-interactive antibiotics derived from various Streptomyces species and examples include antitumour agents such as DC-81 and tomaymycin. 6 They exert their biological activity through covalent binding to the C2-NH 2 of guanine within the minor groove of DNA (Figure 1a) . PBD monomers span three DNA base pairs with a preference for Pu-G-Pu (where Pu = purine; G = guanine) sequences and block transcription by inhibiting RNA polymerase activity in a sequence-specific manner. 7 The potency, DNAbinding affinity and sequence specificity of PBDs have been markedly improved by linking two PBD units through their C8/C8 00 positions to form a PBD dimer that can cross-link appropriately separated guanines on opposite DNA strands. 8 PBD units tethered through a three-carbon diether linkage are able to bind selectively to regions of DNA that are 6-7 bp in length. For example, the PBD dimer SJG-136 ( Figure 1b ) predominantly binds covalently to embedded 5 0 -Pu-GATC-Py sequences by cross-linking opposite-strand guanines separated by 2 bp, with little or no disruption of DNA secondary structure. 8, 9 Sequence-selective recognition can be further enhanced by extension of the linker joining the two PBD monomers. Thus, use of a five-carbon diether linker ( Figure 1 ) facilitates selective binding to include an additional base pair and effects cross-linking of 5 0 -Pu-GATTC-Py and 5 0 -Pu-GAATC-Py sequences. 8 In this study, we report the in vitro antibacterial activity of the three PBD dimers SJG-136, DRG-16 and ELB-21.
Materials and methods

Materials
PBD dimers SJG-136, DRG-16 and ELB-21 ( Figure 1 ) were designed and synthesized according to previously described procedures. 10, 11 Paper discs impregnated with oxacillin, vancomycin, trimethoprim, amikacin, gentamicin, tetracycline, rifampicin, ciprofloxacin, erythromycin and clindamycin were used to determine bacterial susceptibility to these antibiotics and were purchased from Oxoid (Basingstoke, UK).
Bacterial strains
The international collection of 38 MRSA clinical isolates 12 used in this study was assembled at the Royal Free and University College Medical School (RFUCMS), London. The 20 VRE, 12 Streptococcus pyogenes, 12 Streptococcus agalactiae, 12 Listeria monocytogenes, 6 Klebsiella spp., 6 Pseudomonas aeruginosa, 6 Acinetobacter spp., and 6 Proteus mirabilis strains were isolated from clinical specimens at the RFUCMS and were the gift of Professor Jeremy HamiltonMiller. Mycobacterium aurum, M. smegmatis, M. fortuitum, M. abscessus, and M. phlei were obtained from previously described sources. 13 
MIC assays
In vitro susceptibilities were determined by the NCCLS broth microplate assay; 0.1 mL of dilutions of the test compound in Mueller-Hinton broth (Oxoid) were added to 0.1 mL aliquots of bacterial suspension to give a final bacterial count of 10 5 cfu/mL. MIC determinations for mycobacterial strains were performed as previously described. 13 PBD dimers were dissolved in methanol prior to dilution in broth; appropriate concentrations of methanol were incorporated into controls to ensure that the low concentrations of solvent used had no effect on the growth of test strains.
Kinetics of bacterial killing
Mid-logarithmic or stationary phase bacteria in Mueller-Hinton broth (10 6 cfu/mL) were exposed to appropriate concentrations (MIC; MIC ·2; MIC ·4) of PBD dimers and viable counts performed at various time points following incubation with agitation (200 orbits per min on an orbital shaker) at 37 C. Experiments were carried out in duplicate.
Electron microscopy
Negatively stained images were obtained as described previously. 14 
Post-antibiotic effect (PAE)
Mid-logarithmic phase bacteria growing in Mueller-Hinton broth were incubated at 37 C in the presence of various concentrations of the PBD dimer for 1 h. The agent was removed by centrifugation and the cells washed with pre-warmed PBS. The pellet was suspended in pre-warmed Mueller-Hinton broth, incubated at 37 C and bacterial numbers determined over a 24 h period by viable counting. The PAE was calculated by the standard equation T-C, where T is the time taken for the viable count of the compound-treated culture to increase 10-fold after removal of the agent and C is the time taken for the untreated control to increase 10-fold under the same conditions.
Melting curves of duplex DNA
Genomic DNA was prepared from MRSA strains by guanidium thiocyanate extraction according to Pitcher et al. 15 The DNA was washed with ethanol and dissolved in 10 mM Na 2 HPO 4 containing 1 mM EDTA (pH 7.0) to give a concentration of 50 mM. Melting curves were determined spectrophotometrically (l 260 ) in a heated chamber with a controlled increase in temperature of 1 C/min over the range 40-98 C. Optical data were imported into the Origin 5 computer package (MicroCal Inc, Northampton, MA, USA) for analysis and the melting temperature T m determined at the midpoint of the normalized melting profiles using a published procedure. 16 PBD dimers (20 mM) were added to the DNA and incubated at 37 C for 1 h prior to determination of the melting profile.
Results
In vitro antibacterial activity
We determined the antibacterial activity of three PBD dimers (SJG-136, DRG-16 and ELB-21) with differing potencies and sequence selectivities against 94 Gram-positive isolates, 30 Gramnegative isolates and five atypical mycobacteria (Table 1 ). All Gram-negative isolates were insensitive to all three dimers, with MIC 90 values greater than 16 mg/mL; strains could be sensitized by perturbation of the outer membrane with 1 mM EDTA, indicating that this structure precluded the agents from entering the cell. In contrast, all Gram-positive isolates were susceptible to the three dimers with MIC 90 values below 1 mg/L in all cases. The most potent compound was ELB-21, with MIC 90 values of 0.03 mg/L for MRSA and 0.06 mg/L for VRE. Overall, DRG-16 proved more potent than SJG-136 and all three compounds showed good activity against mycobacteria. There was little or no variation in susceptibility to each compound among isolates from any one species; this is exemplified in Table 1 , which summarizes MIC data for the 38 MRSA isolates. Disc diffusion assays using the antibiotics listed in the Materials and methods section provided no evidence of cross-resistance between the three PBD dimers and other antibiotics (data not shown).
Bactericidal activity of PBD dimers
The capacity of ELB-21 to kill EMRSA-16 and VRE was determined. As can be seen from Figure 2 , ELB-21 exhibited potent bactericidal activity against logarithmic phase EMRSA-16 cells. Stationary phase cells were also efficiently killed by ELB-21 and the curves obtained were similar to those for logarithmic phase cells (data not shown). The re-growth that occurred after 24 h was not due to the emergence of resistant genotypes. Logarithmic phase VRE cells were highly susceptible to killing by ELB-21, with a five-log reduction in viability after 4 h incubation at the 
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MIC. Incubation of EMRSA-16 with ELB-21 at the MIC for 4 h resulted in a marked degree of morphological heterogeneity and drug-induced lysis (Figure 3 ), suggesting that ELB-21 inhibits the transcription of a multiplicity of key genes.
PAE
In vitro PAEs for EMRSA-16 and VRE were determined against ELB-21 over a range of concentrations. At the MIC, the PAEs for the two strains were 1.5 and 3.5 h, respectively. The PAE for VRE could not be determined at concentrations above the MIC due to rapid bacterial killing at these concentrations. PAEs against MRSA-16 at twice and four times the MIC were 1.5 and 3.5 h, respectively.
DNA melting
Covalent cross-linking of the two strands of the DNA duplex will increase the temperature required to denature the complex; 17 melting of the complex results in a large increase in absorbance that can be monitored spectrophotometrically. Addition of 20 mM of either DRG-16 or ELB-21 to genomic EMRSA-16 DNA had a profound effect on the T m : DRG-16 raised the T m by, typically, 28.07 C (from 66.70 to 94.77 C) and ELB-21 by 30.81 C (error -0.1 C).
Discussion
The large majority of currently useful antibacterial agents have been derived from natural products produced by microorganisms forced to compete for nutrients in hostile habitats such as soil. The majority of targets for clinically useful natural and semi-synthetic antibiotics are enzymes or structural proteins involved in essential pathways of macromolecule synthesis and most of these have been extensively exploited for antibiotic development. Naturally occurring antibacterial agents such as distamycin, anthramycin and chromomycin that inhibit gene transcription by binding selectively to specific sequences of duplex DNA have been known for many years 18 but it is only recently that efforts have been made to develop such agents as antibacterial drugs. Even though the simplest DNA binding antibiotics show selectivity for various sequence motifs, 18 they are generally cytotoxic and appear unattractive as candidates for the treatment of infection in humans. However, the increasing prevalence of multidrug resistance, associated, in particular, with nosocomial pathogens has created circumstances under which such molecules may have therapeutic utility.
PBD dimers are attracting interest as potential therapeutics for the treatment of various cancers due to their capacity to recognize and cross-link DNA in a sequence-selective manner. In particular, the PBD dimer SJG-136, which produces interstrand cross-links at embedded Pu-GATC-Py target sites within duplex DNA, 8, 9 is currently in Phase I clinical development. 19 This compound, comprised of two PBD units tethered through a three-carbon diether linkage (Figure 1 ), possesses potent bactericidal activity against the five species of Gram-positive bacteria used in this study (Table 1) and, in particular, all MRSA and VRE isolates proved to be highly susceptible. Searching the EMRSA-16 genome 20 using the Artemis genome viewer (www.sanger.ac.uk/Software/Artemis) indicated that the preferred SJG-136 binding sequence AGATCT 8,9 occurs 162 times within coding sequences, including pseudo-genes, and 109 times within non-coding regions of the EMRSA-16 genome; cross-linking at these sites is highly likely to account for its observed in vitro potency.
Loadman and coworkers have shown that after intraperitoneal administration of SJG-136 to NCR/Nu mice at the MTD (0.2 mg/ kg), SJG-136 shows a favourable pharmacokinetic profile:
19 high peak plasma concentrations of C max = 336 nM at 30 min after dosing were observed. A calculated terminal t 1/2 of 0.98 h and AUC of 0.34 mM·h resulted in a clearance rate of 17.7 mL/min per kg. Furthermore, the dimer appeared to bind only moderately to plasma proteins. These data indicate that a therapeutic index for BPD dimers as antibacterial agents is achievable, at least in the case of SJG-136, as plasma drug concentrations are more than 10-fold higher than those required for antibacterial efficacy in vitro. These authors define the term 'maximum tolerated dose' that we used in the context of this study.
The PBD units within DRG-16 and ELB-21 are tethered through a five-carbon diether linker, rather than three as is the case for SJG-136 (Figure 1) , and both are thought to recognize and bind to Pu-GAATC-Py sequences; 8 these compounds, particularly ELB-21, are more potent than SJG-136 (Table 1) . In contrast to distamycin-based polyheterocyclic antibiotics that, like vancomycin, are bactericidal against staphylococci but bacteriostatic against enterococci, 4 PBD dimers are bactericidal against both MRSA and VRE with a significant PAE. Modelling of the interstrand DNA minor-groove cross-linked adducts formed with PBD dimers indicates that there is little or no disruption of DNA secondary structure including base-mispairing and that induced distortion effects are absent. 10 As these compounds are well accommodated within the minor groove such that little of either PBD unit remains exposed beyond the periphery of the host DNA duplex, the complexes are resistant to repair enzymes that are reliant on tracing distortion or helical perturbation in DNA. Both halves of the dimer behave in an essentially identical fashion without disruption of DNA integrity, and the flexible regions linking the two subunits make favourable non-bonding contacts with the floor and walls of the minor groove to enhance overall binding. 10 It is likely that the failure of repair surveillance mechanisms to detect sites of cross-linking accounts in large part for the bactericidal nature of these molecules as interstrand crosslinks, if not repaired, will interfere with the process of DNA replication and result in cell death.
In conclusion, the preliminary data presented here indicate that these compounds exert their antibacterial effects by cross-linking duplex DNA at selected sites on the bacterial genome and these observations are currently being extended using a variety of techniques to quantify the extent and selective nature of the cross-linking process. The compounds appear to cross the bacterial cytoplasmic membrane efficiently but are unable to traverse the outer membrane of Gram-negative bacteria. The molecular weights of these relatively hydrophilic compounds fall within the 500-600 Da range and it is not therefore surprising that they are excluded from passage through the protein channels of this barrier. 21 There may, however, be scope for synergy with compounds that disrupt the integrity of the outer membrane.
The basis of the increase in antibacterial potency of PBD dimers resulting from extension of the linker region is at present unclear and we are investigating whether these changes are accompanied by increases in cytotoxicity or genotoxicity. The potency of this new class of agents against Gram-positive bacteria is high and there appears to be an opportunity for the design of sequence-selective dimers that have a high affinity for motifs within the DNA of key Gram-positive pathogens.
